This approach identified co-activators appeared to be commonly enriched in gene sets that resulted from changes to RARγ (e.g., knockdown of RARγ in RWPE-1, n = 47), and DEGs associated with the miR-96/RARγ/TACC1 axis in TCGA-PRAD tumors (n = 49). The gene discussed is TACC1; the disease is prostate adenocarcinoma.